ADARx Pharmaceuticals (NASDAQ:ADRX) Stock Picked Up by Analysts at UBS Group

Research analysts at UBS Group began coverage on shares of ADARx Pharmaceuticals (NASDAQ:ADRX) in a report released on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. UBS Group’s price target indicates a potential upside of 104.32% from the company’s current price.

ADRX has been the topic of a number of other research reports. TD Cowen began coverage on shares of ADARx Pharmaceuticals in a research report on Tuesday. They issued a “buy” rating on the stock. Wall Street Zen raised shares of ADARx Pharmaceuticals to a “hold” rating in a research note on Saturday, October 3rd. Morgan Stanley began coverage on shares of ADARx Pharmaceuticals in a research report on Tuesday. They set an “overweight” rating and a $32.00 price target for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of ADARx Pharmaceuticals in a research report on Tuesday. They set an “overweight” rating and a $38.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to MarketBeat.com, ADARx Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $35.00.

ADARx Pharmaceuticals Stock Down 3.1%

Shares of ADRX opened at $17.13 on Tuesday. ADARx Pharmaceuticals has a fifty-two week low of $16.61 and a fifty-two week high of $23.21.

Insider Transactions at ADARx Pharmaceuticals

In related news, Director Erez Chimovits purchased 61,516 shares of ADARx Pharmaceuticals stock in a transaction that occurred on Monday, September 28th. The shares were bought at an average price of $17.00 per share, for a total transaction of $1,045,772.00. Following the completion of the transaction, the director directly owned 9,292,025 shares of the company’s stock, valued at $157,964,425. This represents a 0.67% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Sr One Capital Management, Llc purchased 1,600,000 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The stock was bought at an average cost of $17.00 per share, with a total value of $27,200,000.00. Following the completion of the purchase, the insider owned 5,554,094 shares of the company’s stock, valued at $94,419,598. This represents a 40.46% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 3,261,516 shares of company stock valued at $55,445,772.

ADARx Pharmaceuticals Company Profile

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target disease-driving proteins through RNA-based technologies. The company’s platform is designed to support potent and durable control of protein production, with the goal of creating therapies that may be administered less frequently than conventional treatments.

ADARx is advancing a pipeline of investigational therapeutics for conditions involving the kallikrein-kinin and complement pathways, which are implicated in hereditary angioedema and other immune-mediated or inflammatory diseases.